4815-51-4

Basic information

• Product Name: (2,4-Dinitro-phenyl)-pyrrol-1-yl-amine
• Synonyms: (2,4-Dinitro-phenyl)-pyrrol-1-yl-amine
• CAS NO: 4815-51-4
• Molecular Weight: 248.198
• Mol File: 4815-51-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (2,4-Dinitro-phenyl)-pyrrol-1-yl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (2,4-Dinitro-phenyl)-pyrrol-1-yl-amine(4815-51-4)
• EPA Substance Registry System: (2,4-Dinitro-phenyl)-pyrrol-1-yl-amine(4815-51-4)

Safety Data

• Hazardous Substances Data: 4815-51-4(Hazardous Substances Data)

Upstream product

• 119-26-6 (2,4-dinitro-phenyl)-hydrazine 
• 42216-75-1 succindialdehyde bis-2,4-dinitrophenylhydrazone 

Relevant articles and documents

Formation pathways of γ-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil

Tegafur (FT) is a 5-fluorouracil (5-FU) prodrug that has been clinically used for various cancer chemotherapies. The following metabolites of FT were identified in patients: 5-FU, fluoro-β-alanine, and γ-butyrolactone (GBL) and its acidic form, γ-hydroxybutyrate (GHB). GBL/GHB, which is probably generated from the furan ring of FT, inhibits tumor cell angiogenesis, contributing to the antitumor effect of FT-based therapies. In the present study, we identified the metabolites formed from the furan ring of FT by CYP2A6 and thymidine phosphorylase (TPase) using 2,4-dinitrophenylhydrazine derivatization procedures and clarified the metabolic pathway of FT to GBL/GHB. Succinaldehyde (SA) and 4-hydroxybutanal (4-OH-BTL) were produced as the metabolites because of the cleavage of the furan ring of FT during its conversion to 5-FU in cDNA-expressed CYP2A6 and purified TPase, respectively; however, GBL/GHB was hardly detected in cDNA-expressed CYP2A6 and purified TPase. GBL/GHB was formed after human hepatic microsomes or cDNA-expressed CYP2A6 mixed with cytosol were incubated with FT. Furthermore, 4-OH-BTL was converted to GBL/GHB in the microsomes and cytosol. These results suggest that GBL/GHB is generated from FT through the formation of SA and 4-OH-BTL but not directly from FT. Furthermore, the amount of 5-FU and GBL/GHB formed in the hepatic S9 was markedly decreased in the presence of a CYP2A6 inhibitor, suggesting that GBL/GHB may be mainly generated through the CYP2A6-mediated formation of SA. Copyright